Cyclobenzaprine, sold under the brand name Flexeril among others, interacts dangerously with a surprisingly long list of medications. The most critical ones to avoid fall into a few broad categories: drugs that raise serotonin levels, drugs that depress the central nervous system, and drugs with anticholinergic effects. Because cyclobenzaprine is structurally almost identical to older tricyclic antidepressants, it carries many of the same interaction risks those drugs do, even though it is prescribed as a simple muscle relaxant.
Serotonin-Raising Drugs and the Risk of Serotonin Syndrome
The single most dangerous category of drugs to combine with cyclobenzaprine is anything that boosts serotonin in the brain. Cyclobenzaprine blocks the serotonin transporter and the norepinephrine transporter, and it also binds to multiple serotonin receptors.1PubMed Central. Linking pharmacology to clinical reports: cyclobenzaprine and its possible association with serotonin syndrome When you stack it with another drug that increases serotonin activity, the combined effect can push the system past a tipping point into serotonin syndrome, a potentially life-threatening condition marked by agitation, rapid heart rate, muscle rigidity, high body temperature, and in severe cases, seizures or organ failure.
Documented cases of severe serotonin syndrome have occurred when cyclobenzaprine was given alongside the MAOI phenelzine and separately alongside the SNRI duloxetine. In both reported cases, symptoms of autonomic instability and severe agitation appeared within hours of starting cyclobenzaprine and took up to three days to fully resolve after the offending drugs were stopped.2PubMed. Serotonin syndrome from the interaction of cyclobenzaprine with other serotoninergic drugs The drugs that fall into this danger zone include:
- MAOIs: phenelzine, tranylcypromine, selegiline, isocarboxazid. This combination is considered an absolute contraindication. Cyclobenzaprine should not be used within 14 days of taking an MAOI.
- SSRIs: fluoxetine, sertraline, paroxetine, citalopram, escitalopram.
- SNRIs: duloxetine, venlafaxine, desvenlafaxine, milnacipran.
- Tricyclic antidepressants: amitriptyline, nortriptyline, desipramine. Combining cyclobenzaprine with these is essentially doubling up on the same drug class.
- Tramadol and fentanyl: both opioids with serotonergic activity on top of their pain-relieving effects.
- Triptans: sumatriptan, rizatriptan, and other migraine medications in this class.
- St. John’s Wort: an herbal supplement that meaningfully increases serotonin levels.
The risk is not theoretical. A large pharmacovigilance analysis of FDA adverse event reports found that serotonin syndrome was among the adverse reactions persistently linked to cyclobenzaprine even when researchers looked at cases involving the drug alone.3Frontiers in Medicine. Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System When other serotonergic drugs are added on top, the probability climbs further. If you take any antidepressant, make sure your prescriber knows before starting cyclobenzaprine.
Opioids and Other Central Nervous System Depressants
Cyclobenzaprine is itself a sedating drug. Mixing it with other substances that slow brain activity compounds the drowsiness and can depress breathing to a dangerous degree. Opioid prescribing guidelines specifically caution against prescribing opioids alongside skeletal muscle relaxants like cyclobenzaprine because of this additive central nervous system depressant effect.4PubMed. Risk of Opioid Overdose Associated With Concomitant Use of Opioids and Skeletal Muscle Relaxants: A Population-Based Cohort Study Yet in practice, many people with back pain or musculoskeletal injuries end up with both an opioid and a muscle relaxant on the same prescription list, sometimes from different doctors who are unaware of each other’s prescriptions.
Beyond opioids, other CNS depressants to be cautious with include benzodiazepines (diazepam, lorazepam, alprazolam), sleep medications like zolpidem, barbiturates, and gabapentinoids such as gabapentin and pregabalin. Alcohol belongs on this list too. Having a few drinks while taking cyclobenzaprine intensifies drowsiness and impairs coordination well beyond what either would produce alone. There is no safe threshold here; even moderate alcohol intake with cyclobenzaprine can make you a hazard behind the wheel or on your feet.
Anticholinergic Drugs and Stacking Side Effects
Cyclobenzaprine has strong anticholinergic properties, meaning it blocks the neurotransmitter acetylcholine. This is what causes the dry mouth, blurred vision, constipation, and difficulty urinating that many people notice while taking it. The FDA adverse event analysis found that urinary retention, elevated heart rate, changes in mental status, and agitation were all persistently associated with cyclobenzaprine use, even when no other drugs were involved.3Frontiers in Medicine. Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System
When you combine cyclobenzaprine with other anticholinergic drugs, those effects pile up. This is sometimes called anticholinergic burden. Drugs that add to it include older antihistamines like diphenhydramine (Benadryl) and doxylamine (found in many nighttime cold formulas), antipsychotics such as quetiapine and olanzapine, bladder medications like oxybutynin, and some antidepressants already mentioned in the serotonin section above. The concern is not just discomfort. In older adults especially, high anticholinergic burden raises the risk of confusion, falls, heat stroke (because sweating is impaired), and acute urinary retention that may need a catheter to resolve.
This matters for over-the-counter shopping. Many nighttime pain relievers and cold medicines contain diphenhydramine or doxylamine right alongside acetaminophen. If you pick up a “PM” branded pain product while also taking cyclobenzaprine, you are stacking two anticholinergic, sedating drugs without necessarily realizing it. Read labels carefully.
Drugs That Slow Cyclobenzaprine’s Metabolism
Cyclobenzaprine is broken down in the liver primarily by two enzyme families: CYP3A4 and CYP1A2, with CYP2D6 playing a minor supporting role.5PubMed. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine If you take a drug that inhibits either of those main enzymes, cyclobenzaprine clears from your body more slowly, effectively raising the dose your tissues are exposed to. Higher blood levels mean stronger sedation, more anticholinergic side effects, and a greater risk of toxicity.
Common CYP3A4 inhibitors include the antifungal ketoconazole, the antibiotic clarithromycin, and certain HIV protease inhibitors like ritonavir. Grapefruit juice is also a well-known CYP3A4 inhibitor. On the CYP1A2 side, the antibiotic ciprofloxacin and the antidepressant fluvoxamine are potent inhibitors. Even heavy caffeine intake competes for CYP1A2, though the clinical significance of that interaction with cyclobenzaprine is probably minimal for most people.
This metabolic pathway also matters for people with liver disease. If your liver is not functioning well, it cannot clear cyclobenzaprine at a normal rate, and the drug accumulates. The prescribing information for cyclobenzaprine recommends against its use in moderate to severe hepatic impairment, and even mild impairment calls for a lower dose and more caution.
Driving Impairment Is Measurable and Significant
One interaction people rarely think about is cyclobenzaprine and driving. In a controlled study comparing the muscle relaxant tolperisone to placebo and cyclobenzaprine, cyclobenzaprine caused significant driving impairment on the first, second, and third days of use. On the first day, roughly 59% of subjects taking cyclobenzaprine had an increase in lane-weaving that exceeded the threshold associated with elevated crash risk. By the second day, that figure was still about 45%.6PubMed Central. An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine
This level of impairment happens with cyclobenzaprine alone at standard doses. Layer any of the interacting drugs discussed above on top of it, and driving ability deteriorates further. If you are taking cyclobenzaprine alongside an opioid, a benzodiazepine, or even a nighttime antihistamine, operating a vehicle is genuinely unsafe, regardless of how alert you feel subjectively. The impairment tends to be worst on the first few days of use before partial tolerance develops, but the study data show that it persists into at least the third day.
Why Cyclobenzaprine Acts Like a Tricyclic Antidepressant
Much of what makes cyclobenzaprine interact with so many drugs comes down to its chemical structure. It differs from amitriptyline, one of the classic tricyclic antidepressants, by only a single double bond. This near-identical structure means cyclobenzaprine hits many of the same receptors and transporters that tricyclic antidepressants do: serotonin and norepinephrine reuptake blockade, anticholinergic receptor blockade, and histamine receptor blockade (which is where the sedation comes from).7PubMed Central. Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity
This structural kinship explains why cyclobenzaprine overdoses look a lot like tricyclic antidepressant overdoses, though generally less severe. A five-year review of cyclobenzaprine toxicity cases found that the most common effects of overdose were lethargy, rapid heart rate, and agitation. All symptomatic cases showed symptoms within four hours of ingestion. Importantly, the review found that serious toxicity requiring treatment beyond basic decontamination did not occur with ingestions under 100 mg, and the drug did not produce life-threatening cardiovascular or neurologic effects at doses below 1,000 mg.8The Journal of Emergency Medicine. Five-year multicenter retrospective review of cyclobenzaprine toxicity That is somewhat reassuring compared to tricyclic antidepressants, where much smaller overdoses can be fatal. But it does not mean overdose is safe: rhabdomyolysis (severe muscle breakdown) has been documented in cyclobenzaprine overdose cases.7PubMed Central. Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity
Understanding this tricyclic-like pharmacology is useful because it gives you a mental shortcut. If a drug interaction warning exists for amitriptyline, there is a good chance the same warning applies to cyclobenzaprine, even if it is not always spelled out on the pharmacy handout.
Signals the FDA Data Reveals Beyond the Drug Label
The comprehensive pharmacovigilance analysis of FDA adverse event reports turned up some findings that are not part of cyclobenzaprine’s official labeling. In addition to the expected anticholinergic and serotonergic adverse events, the data showed signals for drug abuse, completed suicide, toxicity from combined agents, and drug interaction events that were not detailed on the label.3Frontiers in Medicine. Cyclobenzaprine-related adverse events: a comprehensive pharmacovigilance analysis using the FDA Adverse Event Reporting System The abuse signal is worth paying attention to. Cyclobenzaprine is not a controlled substance in the United States, and it is sometimes dismissed as a low-risk drug. But some people use it recreationally for its sedating effects, often in combination with other substances, and the adverse event data suggest this is a real pattern rather than anecdotal noise.
The suicide signal is harder to interpret from pharmacovigilance data alone, because people taking cyclobenzaprine for chronic pain may already be at elevated risk for depression and suicidal ideation due to their underlying condition. Still, the presence of this signal in the data is a reason to exercise caution when prescribing cyclobenzaprine to someone with a known mood disorder, particularly if they are already on medications that interact with it.
Cyclobenzaprine During Pregnancy and Breastfeeding
Formal safety data on cyclobenzaprine in pregnancy are limited, so most prescribers avoid it unless the benefit clearly outweighs the unknown risk. For breastfeeding, one study directly measured cyclobenzaprine concentrations in human milk and found them to be low, with the calculated infant dose coming to about 0.5% of the weight-adjusted maternal dose.9PubMed. Transfer of Cyclobenzaprine into Human Milk and Subsequent Infant Exposure That is a reassuringly small number. However, because of cyclobenzaprine’s sedating properties, the researchers recommended that infants be regularly assessed for signs of excess sleepiness or poor feeding if the mother continues the drug while nursing.
This is one of those situations where the interaction is not with another drug but with a vulnerable person. An infant’s ability to metabolize drugs is far less mature than an adult’s, so even small exposures carry proportionally more risk. If you are breastfeeding and need a muscle relaxant, talking through the options with your doctor makes sense rather than assuming cyclobenzaprine is fine because the transfer into milk is low.
Practical Tips for Avoiding Dangerous Combinations
The sheer number of interactions can feel overwhelming, but a few habits make the risk manageable. First, treat cyclobenzaprine as you would an antidepressant when evaluating drug interactions, because pharmacologically, it behaves like one. If a new prescription or OTC product carries a warning about tricyclic antidepressants, pay attention. Second, give your pharmacist a complete list of everything you take, including supplements like St. John’s Wort and over-the-counter sleep aids. Pharmacists catch drug interactions for a living, and their software will flag cyclobenzaprine combinations that your prescriber may not have considered.
Third, be especially careful in the first few days of starting cyclobenzaprine. Both serotonin syndrome and severe CNS depression tend to show up quickly after the interacting combination begins. If you notice unusual agitation, muscle twitching, a racing heart, excessive sweating, or confusion within hours to days of starting cyclobenzaprine, those are red flags that warrant immediate medical attention. Fourth, if you are over 65, the risks are amplified across the board. Older adults clear cyclobenzaprine more slowly, are more sensitive to its anticholinergic effects, and are more likely to be on multiple medications that interact with it. Many geriatric prescribing guidelines recommend avoiding cyclobenzaprine entirely in this age group.
Finally, do not assume that because cyclobenzaprine is a “just a muscle relaxant,” it is mild. Its pharmacology is complex, its interaction profile is broad, and its sedating effects are measurable enough to impair driving at standard doses. Respect it accordingly, and it can do its job without causing trouble.